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Background. Despite a lack of clear evidence, multiple neurostimulants are commonly provided after severe brain injury (BI).
The purpose of this study is to determine if the number of neurostimulants received during rehabilitation was associated with
recovery of full consciousness or improved neurobehavioral function after severe BI. Method. Data from 115 participants were
extracted from a neurobehavioral observational study database for this exploratory, retrospective analysis. Univariate optimal data
analysis was conducted to determine if the number of neurostimulants influenced classification of four outcomes: recovery of full
consciousness during rehabilitation, recovery of full consciousness within one year of injury, and meaningful neurobehavioral
improvement during rehabilitation defined as either at least a 4.7 unit (minimal detectable change) or 2.58 unit (minimal clinically
important difference) gain on the Disorders of Consciousness Scale-25 (DOCS-25). Results. Number of neurostimulants was not
significantly (𝑃 > 0.05) associatedwith recovery of full consciousness during rehabilitation, within one year of injury, ormeaningful
neurobehavioral improvement using the DOCS-25. Conclusions. Receiving multiple neurostimulants during rehabilitation may
not influence recovery of full consciousness or meaningful neurobehavioral improvement. Given costs associated with additional
medication, future research is needed to guide physicians about the merits of prescribing multiple neurostimulants during
rehabilitation after severe BI.
1. Introduction
Severe brain injury (BI) results in loss of consciousness for
a period of time greater than 24 hours. The transition
from unconsciousness to recovery of full consciousness is
described clinically according to three states of disordered
consciousness: comatose, vegetative state (VS), and the mini-
mally conscious state (MCS). Each state is defined by varying
levels of arousal and awareness, ranging from the absence
of arousal and sleep wake cycles in the comatose state to
inconsistent but definite behavioral indicators of self- or
environmental awareness in MCS [1–6].
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Common practice in medical rehabilitation of people in
states of disordered consciousness is to provide neurophar-
macological interventions while the patient is transitioning
through the states of disordered consciousness and provi-
sion is usually continued after emergence from MCS to a
state of full consciousness [7]. Neurostimulants, specifically,
are provided to manage arousal states which often means
enhancing neural transmission [8]. The general mechanisms
of action for neurostimulants are increases in the synaptic
concentration of dopamine, serotonin, and noradrenaline in
various brain regions [9–14]. Neurobehavioral and neurocog-
nitive gains ascribed to neurostimulants include enhanced
arousal, wakefulness, awareness, attention, memory, mental
processing speed, and/or motor processing speed [7, 8].
However, neurostimulants are commonly provided to
this patient population, and, until recently, there was lim-
ited evidence to support the use of neurostimulants to
improve neurobehavioral function and facilitate recovery of
consciousness among people in states of disordered con-
sciousness. A randomized placebo-controlled trial published
in 2012 demonstrated that a widely used neurostimulant,
amantadine, is efficacious in accelerating neurobehavioral
function among people in VS or MCS between 4 and 16
weeks after traumatic brain injury (TBI) [15]. Evidence for
efficacy of other neurostimulants alone or in combinations
such as methylphenidate is inconclusive and derived from
case reports, cross-over studies of short durations where the
subjects serve as their own controls (e.g., while on/off medi-
cation or over two to three days), and one meta-analysis [16].
However, off-label prescribing of neurostimulants occurs
routinely [7].
Since, there is no evidence to date supporting prescription
of multiple neurostimulants to people in states of disor-
dered consciousness after BI for the purpose of enhancing
arousal, awareness, and neurobehavioral function, we con-
ducted exploratory analyses to provide insights about the
relationship between the provision of multiple neurostim-
ulants during rehabilitation hospitalization and recovery.
The purpose of this study is to assess whether receiving
multiple neurostimulants is associated with recovery of full
consciousness or improved neurobehavioral function after
severe BI.
2. Materials and Methods
The study sample for this paper included 115 participants
selected from a larger study database of 191 people with severe
brain injury (BI) who (a) were admitted to a rehabilitation
hospital within 180 days of injury, (b) were ≥18 years of
age at time of injury, (c) experienced unconsciousness for
≥28 consecutive days, and (d) had a severe BI that was
not due to cancer, tumors, and inflammatory, infectious,
and/or toxic metabolic encephalopathies. For our study
sample, we included only those individuals from the larger
study who had medication data and were provided at least
one neurostimulant (amantadine, bromocriptine, levodopa,
methylphenidate, and modafinil) during rehabilitation. Par-
ticipants for the larger study were recruited from two
freestanding inpatient rehabilitation facilities, one long-term
acute care hospital providing rehabilitation, two Department
of Veterans Affairs hospitals providing acute rehabilitation,
and one subacute nursing facility. The study was approved
by each facility’s human subjects institutional review board.
Each research participant was followed from time of rehabili-
tation admission through the first year of recovery tomonitor
time to full consciousness.
2.1. Data Collection and Instrumentation. Data collection
procedures for the larger study included medical record
reviews and bedside neurobehavioral assessments during
rehabilitation hospitalization and monthly telephone follow-
up to assess the recovery of full consciousness up to one year
after injury.The data for the study sample were collected from
1997 to 2010.
At time of study enrollment, each participant’s emergency
room, intensive care, and acute care recordswere reviewed for
sociodemographics, medical history, cause of injury, etiology,
and injury-related medical conditions. After review of each
subject’s records, a family/surrogate interview was conducted
to collect any information not obtainable from the records
and/or to confirm information regarding cause of injury.
At time of rehabilitation discharge, all medications
received each day of hospitalization as part of the participant’s
routine medical care were abstracted from the electronic
medical records including start date, stop date, start time, and
stop time for each dose.
2.1.1. Neurobehavioral Functioning Data. During rehabil-
itation hospitalization, neurobehavioral evaluations using
the Disorders of Consciousness Scale-25 (DOCS-25) [17–
19] were conducted weekly until recovery of consciousness
or completion of a sixth DOCS evaluation or discharge
from the rehabilitation facility, whichever came first. The
DOCS-25 is a bedside test administered by allied health
clinicians [20]. Best behavioral responses, elicited with the
25 test stimuli, are scored according to a 3-point scale (0
= no response, 1 = generalized response, and 2 = localized
response). The DOCS has strong interrater agreement (𝜅 =
.95) [17], strong reliability (alpha = .86), and strong person
separation reliability (.91) all of which allow the DOCS
to be used for individual patient measurement [19]. The
DOCS also has excellent measurement precision, captures
a broad range of function, and forms a unidimensional
hierarchywith nomisfitting test items andnodifferential item
functioning across etiologies and gender [19]. There is also
strong evidence of concurrent validity between the DOCS
and theGlasgowComa Scale as well as the Coma/Near-Coma
Scale allowing for distinction between VS and MCS [19].
The recent [19] evidence of strong construct validity supports
earlier findings [17, 19] that each DOCS test item assesses
the same neurobehavioral constructs over six weeks and that
the DOCSmeasures provide independent information about
neurobehavioral functioning throughout the first six months
of the recovery trajectory [17, 18]. The DOCS minimal
detectable change (MDC
90
) is 4.7 indicating that this is the
amount of meaningful change that exceeds measurement
error. The DOCS minimal clinically important difference
(MCID) is 2.58 which corresponds to the smallest amount of
The Scientific World Journal 3
clinically meaningful DOCS change [21]. A final important
note is that the DOCS also has strong prognostic validity for
predicting recovery of consciousness for multiple time points
within the first year of recovery [22] and independence with
expressing needs 1 year after severe BI [23].
For the current study, we examined the total DOCS-25
measure from baseline that is collected at time of rehabilita-
tion admission and the total DOCS-25 change measure. The
total DOCS-25 changemeasure was computed by subtracting
the baseline from the DOCS-25 measure obtained at the
patient’s last assessment. DOCS-25measures were calibrated,
according to rater calibrations, using the FACETSmodel [24]
to account for patient ability, item difficulty, multiple raters,
and repeated DOCS testing. The measures are reported on a
0 to 100 clinical scale [25–27].
2.1.2. Full Consciousness Data. Evaluations to determine
recovery of full consciousness were conducted during reha-
bilitation hospitalization and after rehabilitation discharge.
During rehabilitation hospitalization, evaluations to deter-
mine recovery of full consciousness were conducted 1-2 times
per week. After rehabilitation discharge each participant was
evaluated for full consciousness one time permonth up to one
year after injury.
Full consciousness was defined as requiring external and
internal awareness demonstrated by consistent manifestation
of at least one of three criteria: (1) functional interactive com-
munication, (2) functional use of an object, or (3) another
consistent demonstration of behavior indicating awareness of
the environment. The procedures for evaluating a patient to
determine if they have recovered full consciousness during
rehabilitation and after rehabilitation discharge are separate
from and different than those of the DOCS-25.
The procedures for evaluating recovery of full conscious-
ness are described in detail elsewhere [28]. In brief, the
evaluation for recovery of full consciousness during reha-
bilitation is conducted by allied health clinicians via direct
clinical observation and patient interactions. After discharge,
the evaluation is conducted by clinicians interviewing the
surrogate or caregiver according to a telephone script inclu-
sive of probes to elicit the same behavioral data. Clinicians
probe the surrogate or caregiver to collect the behavioral data
that the surrogates and caregivers are knowledgeable of via
direct observation and patient interactions. This behavioral
information is then usedwith a standardized decisionmaking
algorithm where each decision point is informed by behav-
ioral observation and patient interaction data [28].
The procedures for evaluations during rehabilitation
and after discharge follow-up differ only according to the
methods used to collect the same behavioral data. During
rehabilitation the behavioral data is collected by clinicians via
direct observation and patient interactions. During follow-
up behavioral data is collected over the phone according to
questions and probes made by the clinicians to the surro-
gate or caregiver. The DOCS-25 is not administered during
this follow-up period. The behavioral information collected
during the phone interview is collected via the standardized
clinical probing designed to elicit the same behavioral data
as collected by the surrogate and caregivers via direct obser-
vation of patient interactions. The behavioral data, collected
during rehabilitation and during follow-up, are then used to
inform the decision points on the algorithm used to make a
determination of recovery of full consciousness.
2.1.3. Medication Data. Medications received for each day of
rehabilitation hospitalization as part of the participant’s rou-
tine medical care were recorded according to the start/stop
dates for each dose. Medication data were collected until the
patient recovered full consciousness. The date of recovery
of full consciousness was cross-referenced with medication
data.
2.2. Study Sample. Of the 191 people in the larger study,
medication data could not be obtained for 58 participants
(i.e., missing medication data) (Figure 1). Sixteen people
were not provided any neurostimulants and two people
recovered full consciousness within two days of the baseline
neurobehavioral assessment. After excluding these people,
the final analytic sample for the current study included 115
participants. Of these 115 participants, 84 (73%) received
more than one stimulant and 31 (27%) received only one
neurostimulant.
2.3. Explanatory Variable: Number of Neurostimulants. The
number of neurostimulants received during rehabilitation
hospitalization was made into a binary explanatory variable:
one neurostimulant or two or more neurostimulants (mul-
tiple neurostimulants). This explanatory variable was used
to determine if number of neurostimulants received during
rehabilitation hospitalziation was associated with the study
outcomes.
2.4. Study Outcomes. Four outcome variables were examined
and for this paper we refer to the optimal data analysis “class
variable” [29] as an outcome. All outcomes are binary. The
first two outcomes involved recovery of full consciousness.
The first outcome was whether or not recovery of full
consciousness ocurred during rehabilitation hospitalization.
The second outcome was whether or not recovery of full
consciousness ocurred within one year of injury. The third
and fourth outcomes relate to meaningful neurobehavioral
improvement. The third outcome was whether or not the
participant made a gain in total DOCS-25 change measure
above theDOCS-25MDCof 4.7 [21].The fourth outcomewas
whether or not the participant made a gain in total DOCS-25
change measure above the DOCS-25 MCID of 2.58 [21].
2.5. Data Analyses. Univariate optimal data analysis (Uni-
ODA) was conducted using UniODA software [29]. Univari-
ate ODA is a statistical method that determines the accuracy
that an explanatory variable can predict a patient’s outcome
classification (e.g., did or did not recover full consciousness
or make meaningful neurobehavioral improvement). This
method is ideal given that the purpose of the study is
to examine the relationship between the number of neu-
rostimulants received during rehabilitation and the four
study outcomes. To examine significance of an explanatory
variable, ODA uses Monte Carlo procedures, and leave-
one-out (LOO) resampling was used to examine stability
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Severe TBI database =
191 participants
133 participants
117 participants
Study sample
n = 115 participants
58 excluded
data
16 excluded
• Did not receive
neurostimulants
2 excluded
• Recovered full
consciousness during
acute rehabilitation
Received one 
neurostimulant
n = 31 participants
Received multiple 
neurostimulants
n = 84 participants
∙ Missing medication 
Figure 1: Study sample.
of effect strength sensitivity (ESS) [30]. ESS stability was
examined because it is a normed index of likelihood of
correct outcome classification and because it can be used to
directly compare different UniODAmodels. ESS values range
between 0 (classification accuracy expected by chance) and
100 (errorless classification) [29]. To compute ESS, ODA uses
percentage of accuracy in classification (PAC) as follows [29]:
PAC =
(true positives + true negatives)
𝑁
× 100%,
Mean PAC =
(Se + Sp)
𝐶
× 100%,
ESS = (Mean PAC − 50)
50
× 100%,
(1)
where 𝐶 is number of response categories for the outcome,
which for this study is two for each of the four outcomes
(e.g., recovery of consciousness during rehabilitation or no
recovery of consciousness during rehabilitation); Se = [true
positives/(true positives + false negatives)] × 100; and Sp =
[true negatives/(false positives + true negatives)] × 100.
ESS values, reflecting stability after LOOprocedures, were
compared for each UniODA model. An explanatory variable
is considered LOO stable if ESS does not vary between the
total sample andLOOanalyses on the resampled total sample.
3. Results
3.1. Sample Characteristics. Table 1 summarizes the sample
characteristics for the total sample, one neurostimulant, and
multiple neurostimulants groups.The study sample (𝑛 = 115)
was comprised predominantly of participants who are young
(average age in years = 37 ± 16), Caucasian (75%), and males
(66%). The majority of participants (57%) incurred a closed
head injury. The average number of days between injury and
rehabilitation was 65 ± 75. The average baseline total DOCS-
25 measure was 48.46 ± 13.80 for the total sample, 50.39 ±
16.57 for the one neurostimulant group, and 47.77 ± 12.71
for the multiple neurostimulants groups. The average total
DOCS-25 change measure was 2.35 ± 13.82 for the total
sample, 4.12 ± 12.69 for the one stimulant group, and 1.79 ±
14.20 for the multiple neurostimulants groups. Recovery of
full consciousness during rehabilitation occurred in 43% of
the total sample, 43% of the one neurostimulant group, and
42% of the multiple neurostimulants group. Recovery of full
consciousness within one year of injury occurred in 62% of
the total sample, 57% of the one neurostimulant group, and
64% of the multiple neurostimulants group.
3.2. Frequencies of NeurostimulantMedications. Table 2 sum-
marizes the frequency of neurostimulants received for the
total sample, one neurostimulant, and multiple neurostim-
ulants groups. Methylphenidate was the most common
for the patients who received multiple stimulants (80%),
followed by amantadine (69%) and bromocriptine (48%).
Among patients who received only one neurostimulant,
amantadine was most common (35%), followed closely by
methylphenidate (32%).
3.3. Univariate Optimal Data Analyses (ODA) Results. To
determine whether receiving multiple neurostimulants was
associated with recovery outcomes, a separate UniODA
model was completed for each outcome utilizing number of
neurostimulants (i.e., one or multiple neurostimulants) as
the explanatory variable in each UniODA model. Number
of neurostimulants received was not significantly (𝑃 >
0.05) associated with recovery of full consciousness during
rehabilitation, recovery of full consciousness within one year,
or meaningful neurobehavioral improvement defined by the
DOCS-25 MDC
90
and MCID (Table 3).
4. Discussion
This unique data set collected during rehabilitation after
severe BI allowed for the exploratory analyses of neu-
rostimulants. In this sample, recovery of full consciousness
during and after rehabilitation up to one year after injury
and meaningful improvement in neurobehavioral function
during rehabilitation were not associated with the number of
neurostimulants received during rehabilitation.
Though a recent randomized, placebo-controlled trial
has shown that amantadine is efficacious for facilitating
neurobehavioral recovery after severe BI [15], no studies
have been reported indicating that prescribing multiple
neurostimulants is effective. Findings from our exploratory
analyses suggest, however, that not only did the majority of
the sample receive multiple neurostimulants (73%) but also
recovery of full consciousness and meaningful neurobehav-
ioral improvement are not different for those who received
single or multiple neurostimulants.
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Table 1: Summary of sample characteristics.
Total sample
(𝑛 = 115)
One neurostimulant
(𝑛 = 31)
Multiple neurostimulants
(𝑛 = 84)
Age
(years, mean ± stdev) 36.7 ± 16.3 35.4 ± 12.9 37.2 ± 17.5
Gender Male: 66% (76/115) Male: 81% (25/31) Male: 61% (51/84)
Female: 34% (39/115) Female: 19% (6/31) Female: 39% (33/84)
Ethnicity
(i) Caucasian 75% (86/115) 81% (25/31) 73% (61/84)
(ii) African American 10% (12/115) 6% (2/31) 12% (10/84)
(iii) Asian 3% (4/115) 6% (2/31) 2% (2/84)
(iv) Hispanic 6% (7/115) 0% (0/31) 8% (7/84)
(v) Arabic 2% (2/115) 3% (1/31) 1% (1/84)
(vi) Israeli 1% (1/115) 0% (0/31) 1% (1/84)
(vii) Serbian 1% (1/115) 3% (1/31) 0% (0/84)
(viii) Unknown 2% (2/115) 0% (0/31) 2% (2/84)
Etiology
(i) Closed head injury 57% (66/115) 55% (17/31) 59% (49/84)
(ii) Open head injury 17% (4/115) 9% (3/31) 1% (1/84)
(iii) Anoxic 20% (23/115) 16% (5/31) 21% (18/84)
(iv) Hemorrhagic 5% (6/115) 6% (2/31) 5% (4/84)
(v) Aneurysm 3% (3/115) 3% (1/31) 2% (2/84)
(vi) Blast trauma 3% (3/115) 3% (1/31) 2% (2/84)
(vii) Other 9% (10/115) 6% (2/31) 10% (8/84)
Days between injury and rehabilitation
(days, mean ± stdev) 65 ± 75 71 ± 47 63 ± 83
Percentages represent the valid percent, for which the denominator is the total sample minus the missing participant cases for each specific variable.
Table 2: Neurostimulant medications prescribed during rehabilitation.
Medication Total sample (𝑛 = 115) One neurostimulant (𝑛 = 31) Multiple neurostimulants (𝑛 = 84)
Amantadine 60% (69/115) 35% (11/31) 69% (58/84)
Bromocriptine 41% (47/115) 23% (7/31) 48% (40/84)
Levodopa 2% (2/115) 0% (0/31) 2% (2/84)
Methylphenidate 67% (77/115) 32% (10/31) 80% (67/84)
Modafinil 30% (34/115) 10% (3/31) 37% (31/84)
The majority of our study sample was provided multiple
neurostimulants and yet our findings indicate no association
between use of multiple neurostimulants and improved
outcomes according to four indices of recovery. Given the
common off-label use of neurostimulants [7, 31] and the
dearth of knowledge regarding multiple neurostimulants
prescribing practices, future research is warranted in this
area. One direction towards filling this knowledge gap would
be a data repository collecting off-label neurostimulant med-
ication data and rehabilitation outcome data among people in
states of disordered consciousness worldwide [31] or adding
the collection of neurostimulant medication data to existing
nationwide data repositories. Another randomized clinical
trial, or perhaps a naturalistic open-label clinical trial, may be
warranted to determine if multiple neurostimulants are more
efficacious than a single neurostimulant. The clinical trial
could examine the same outcomes examined here or other
outcomes related to a specific function. Methylphenidate,
for example, may be indicated to enhance processing speed
[7], whereas bromocriptine and levodopa may be indicated
for movement initiation and akinesia [32]. In other words,
one possible explanation for off-label multiple neurostim-
ulants treatment, despite lack of evidence, is that different
neurostimulants may be used to enhance specific aspects of
neurorehabilitation. It is also plausible that multiple neu-
rostimulants were provided one or two times to examine
short term clinical effects to determine which medication if
any helped with a specific function (e.g., arousability, visual
tracking). Future analyses could address this by examining
specific function or cognitive outcomes in order to determine
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Table 3: Univariate optimal data analysis (UniODA) results, neurostimulants as explanatory variable.
Outcome variable UniODA model 𝑁 % satisfied 𝑃 ESS
Recovery of full consciousness
during rehabilitation
If received one neurostimulant, then predict recovery of
consciousness during rehabilitation
30 43.3 1.000 0.8
If received multiple neurostimulants, then predict no
recovery of consciousness during rehabilitation
66 42.4 1.000† −30.9†
Recovery of full consciousness
within one year
If received one neurostimulant, then predict no
recovery of consciousness within one year
30 56.7
0.506 6.8
If received multiple neurostimulants, then predict
recovery of consciousness within one year
70 64.3
Change in total DOCS-25 score
above MDC90 of 4.7
If received one neurostimulant, predict clinically
detectable change in DOCS-25 score
22 40.9
0.800 4.1
If received multiple neurostimulants, predict clinically
nondetectable change in DOCS-25 score
70 35.7
Change in total DOCS-25 score
above MCID of 2.58
If received one neurostimulant, predict clinically
detectable change in DOCS-25 score
22 50.0
0.463 7.4
If received multiple neurostimulants, predict clinically
nondetectable change in DOCS-25 score
70 40.0
𝑁 indicates number of observations in a given predicted class category. % satisfied indicates percentage of observations in a given predicted class category. †
indicates LOO 𝑃 and ESS values reported due to instability. That is, if LOO ESS is lower than training ESS, then the results are not LOO stable.
if the results obtained would change if the sample was
culled to reflect only participants who received multiple
neurostimulants at the same time.
When there is a paucity of evidence on a common clinical
approach, it is of value to conduct exploratory analyses to
examine factors that may guide future research and inform
clinical practice. As such, the reported findings are novel
and informative but should be interpreted in light of study
limitations. First, a larger data set and/or a data set with
other neurobehavioral outcomes (e.g., auditory attention)
and neurophysiological outcomes (e.g., brain stem auditory
evoked potentials), for example, would allow elucidation of
the relationship between receiving multiple neurostimulants
and recovery. Among these neurobehavioral outcomes, it
may be of value to also include additional measures of
neurobehavioral function in future studies such as those
examined in a systematic review in 2010 [33] including the
Coma Near-Coma scale [34], Coma Recovery Scale-Revised
[35], andDisability Rating Scale [36] as well as to compute the
MDC and MCID for these measures. Another limitation is
the lack of side effect data for this sample. Data on side effects
associated with the use of neurostimulants in this population
and side effect profiles could influence which and how many
neurostimulants should be used during rehabilitation.
Future analyses should also consider the cost of these
neurostimulants, as it may be more cost-effective to use only
one neurostimulant rather than more than one if outcomes
are not significantly different [37]. Furthermore, the addition
of qualitative data regarding physicians prescribing practices
may shed light on why certain patients received multiple
neurostimulants and others did not. This type of qualita-
tive data assessment on clinical decision making regarding
neurostimulant prescribing practices could be conducted in
future research studies.
5. Conclusion
Study findings suggest that receiving multiple neurostimu-
lants during rehabilitation hospitalization does not influence
recovery of full consciousness or meaningful neurobehav-
ioral improvement. Future research is needed to determine
whether it is advisable for clinicians to prescribe multiple
neurostimulants during rehabilitation. Given positive find-
ings that amantadine facilitates neurobehavioral function
[15], it may be a better alternative to prescribe a single
neurostimulant consistently such as amantadine.
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